Prime Medicine, Inc. published a research paper by the Watts group reporting a practical strategy for purifying long, structurally complex CRISPR guide RNAs using a 5′-terminal dioctyloxytrityl (DOT) protecting group.
Published
Signal category
Research & Knowledge
Quote
“The Watts group recently reported a practical strategy for purifying long, structurally complex CRISPR guide RNAs using a 5′-terminal dioctyloxytrityl (DOT) protecting group.”
— Wang Yao|Prime Medicine, Inc. team
Company
Prime Medicine, Inc.
Delivering on the promise of Prime Editing
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 186 employees
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.
Founded 2019